Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors

Chunyu Wang, Andreas Rimner, Daphna Y. Gelblum, Jessica Flynn, Andrew Jackson, Ellen Yorke, Abraham J. Wu

JAMA Oncology · 2019 · 44 citations · 6 references

DOIFull text

Open access

Concepts

Abstract

special diets (29 of 1023, 2.9%), acupuncture (26 of 1023, 2.0%), homeopathy (15 of 1023, 1.5%), movement or exercise techniques (11 of 1023, 1.3%), naturopathy (7 of 1023, 0.6%), traditional healers (6 of 1023, 0.4%), energy healing therapy (5 of 1023, 0.6%), biofeedback (5 of 1023, 0.4%), hypnosis (4 of 1023, 0.5%), and craniosacral therapy (2 of 1023, 0.2%). Factors associated with CAM use included white race (AOR, 1.82; 95% CI, 1.28-2.58; P = .001), female sex (AOR, 1.55; 95% CI, 1.26-1.91; P < .001), non-Hispanic ethnicity (AOR, 1.64; 95% CI, 1.05-2.56; P = .03), and younger age (AOR, 1.02 per year; 95% CI, 1.01-1.02; P < .001) (Table Among 1023 participants using CAM, 288 (29.3%) did not disclose CAM use to their physicians. The adjusted rates of nondisclosure for those using herbal supplements was 11.8% and 58.2% for those using mantra/mindfulness/spiritual meditation (Table The most frequently reported reasons for nondisclosure were because the physician did not ask (n = 155 of 288; 57.4%) or participants did not think their physicians needed to know (n = 140 of 288; 47.4%). A smaller proportion of CAM users felt that their physician did not know as much about the therapy (n = 28 of 288; 8.5%), reported they were not given enough time to tell about therapy (n = 12 of 288; 5.7%), expressed concern about a negative reaction (n = 17 of 288; 3.9%), were worried that their physician would discourage use (n = 18 of 288; 3.6%), or reported that physicians discouraged use in the past (n = 11 of 288; 1.9%).

References

6